Head of AI/ML
Head of AI
astrazeneca · 📍 US - Boston - MA
Enterprise AI strategy owner for Alexion's rare disease unit, translating multi-year roadmap into funded, scalable AI products across research, operations, and commercial.
Signals
- ⚠ no reporting line stated
- ⚠ vague/undefined scope — strategy and operating model still evolving at time of posting
- ✓ rare disease unit of a top-5 pharma gives clear domain focus
- ✓ AI portfolio spans R&D, regulatory, commercial — broad enterprise mandate
Company history
AstraZeneca is rapidly scaling AI leadership across multiple units simultaneously, suggesting serious organizational investment rather than isolated experimentation.